Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)

Emerg Microbes Infect. 2015 Jun 17;4(6):e37. doi: 10.1038/emi.2015.37.

Authors

Lu Lu¹, Shuai Xia¹, Tianlei Ying¹, Shibo Jiang¹

Affiliation

¹ Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / pharmacology*
Antibodies, Monoclonal / therapeutic use
Antiviral Agents / pharmacology*
Antiviral Agents / therapeutic use
Communicable Diseases, Emerging / drug therapy*
Communicable Diseases, Emerging / prevention & control
Coronavirus Infections / drug therapy*
Coronavirus Infections / prevention & control
Drug Synergism
Humans
Middle East Respiratory Syndrome Coronavirus / drug effects*
Middle East Respiratory Syndrome Coronavirus / genetics
Middle East Respiratory Syndrome Coronavirus / immunology
Protein Domains
Spike Glycoprotein, Coronavirus / antagonists & inhibitors*
Viral Fusion Protein Inhibitors / pharmacology

Substances

Antibodies, Monoclonal
Antiviral Agents
Spike Glycoprotein, Coronavirus
Viral Fusion Protein Inhibitors